METHOD AND SYSTEM FOR DOING BUSINESS BY MINING THE PLACENTAL-CHORD COMPLEX

• US 20080132803A1
• Filed: 11/15/2007
• Published: 06/05/2008
• Est. Priority Date: 11/30/2006
• Status: Abandoned Application

• Current Assignee: Hyman Friedlander
• Original Assignee: Hyman Friedlander
• Inventors: Friedlander, Hyman
• Application Number:
  US11/940,385
• Publication Number:
  US 20080132803A1
• Time in Patent Office: Days
• US Class Current: 600/562
• CPC Class Codes: A61B 10/00 Other methods or instruments for diagnosis, e.g. instruments for taking a cell sample, for biopsy, for vaccination diagnosis vaccination prophylaxis, vaccination therapy A61B17/20; Sex determination; Ovulation-period determination menstruation tables G06C3/00; Throat striking implements

Abstract

Methods, systems and computer readable code for mining the placenta-umbilical cord complex are disclosed. According to some embodiments, a plurality of distinct components of the placenta-umbilical complex are recovered for a placenta-umbilical cord complex of the donor and stored separately. Methods, systems and computer-readable code for determining which set of distinct components are recovered and stored, and how these components are allocated are disclosed. A method effecting a business transaction related to a placental-umbilical cord complex of a donor is disclosed were a transaction is effected whereby the donor donates a first set of components of the placental-chord complex, and the donor is provided with a private banking service for a second set of components of the placental-chord complex, wherein the first and second sets are distinct. Furthermore, methods systems and computer readable code for determining prices of transactions involving several distinct types of stem cells derived from the placenta-umbilical cord complex of a donor, or involving several different components of the placenta-umbilical the placenta-umbilical cord of a donor are disclosed. Furthermore, methods, systems and computer-readable code for maintaining a computer-based registry for different types of cells derived from the placenta-umbilical cord complex are disclosed.

Claims

1. A method of processing biological matter of the placenta-umbilical complex of a mammalian donor, the method comprising

a) receiving the placenta-umbilical cord complex of the donor,

b) determining a set of at least two distinct components of the placenta-umbilical cord complex to recover and store;

c) recovering said determined components derived from the placenta-umbilical cord complex of the donor; and

d) separately storing each said recovered component.

2. The method of claim 1 wherein said stored components include at least two distinct samples of individual undifferentiated or partially differentiated stem cells, each respective said sample derived a different placenta-umbilical cord complex location.

3. The method of claim 2 wherein said distinct locations are selected from the group consisting of umbilical chord blood, placenta, Wharton Jelly and amniotic fluid.

4. The method of claim 1 wherein said stored components include at least two distinct samples of individual undifferentiated or partially differentiated stem cells, each said sample of a different type, and said cell types are selected from the group consisting of mesenchymal stem cells, hematopoietic stem cells, endothelia progenitor cells, and epithelial progenitor cells.

5. The method of claim 1 wherein a first said component is undifferentiated or partially differentiated cells and a second said component is a generic biomaterial.

6. The method of claim 4 wherein said generic biomaterial is selected from the group consisting of vascular tissue, extra-cellular matrix material cord blood plasma, and membranes.

7. The method of claim 1 wherein said donor is a non-human donor, the method further comprising:

e) designating at least one said stored component for use as a therapeutic agent.

8. The method of claim 1 wherein at least one said stored component is sample of individual undifferentiated or partially differentiated cells, the method farther comprising:

e) performing at least one of subjecting said undifferentiated or partially differentiated individual cells to an ex vivo expansion process and inducing differentiation of the individual cells ex vivo

9. The method of claim 1 wherein the mammalian donor or a mother of the mammalian donor is pre-diagnosed with a genetic disease, at least one said stored component is a sample of mesenchymal stem cells, the method further comprising:

e) designating said mesenchymal stem cells for use in screening a pharmaceutical composition related to said genetic disease.

10. The method of claim 1 wherein at least one said stored component is a sample of individual cells derived from the umbilical cord or the placenta, the method further comprising:

e) designating said individual cells for use in a screening assay for medical product evaluation

11. The method of claim 1 wherein said determining is carried out in accordance with at least one of pricing data, demand data, pricing forecasts, and demand forecasts of placenta-umbilical cord complex components.

12. The method of claim 1 wherein said determining is carried out in accordance with donor type information.

13. The method of claim 12 wherein said determining includes making a determination to store mesenchymal stem cells if said donor type information indicates an elevated risk of a neurological disease.

14. The method of claim 12 wherein said determining includes making a determination to store hematopoietic stem cells if said donor type information indicates an elevated risk of a cancer.

15. The method of claim 1 wherein said determining is carried out in accordance with economic data of the donor.

16. The method of claim 15 wherein said economic data includes at least one of sum of money the donor is willing to pay, an economic status of the donor, and an insurance status of the donor.

17. The method of claim 1 wherein said determining is carried out in accordance with costs of testing at least one of the donor, the relative of the donor, and one or more said components of said placenta-umbilical chord complex.

18. The method of claim 1 further comprising:

e) designating a first set of said stored components for private banking with a first business entity; and

f) offering a second set of said stored components for sale to a second business entity, said first set of components being distinct from said second set of components.

19. The method of claim 18 wherein said first entity is a biological matter bank and second entity is one of a cosmetic industry entity and a pharmaceutical industry entity.

20. A method of effecting a business transaction related to a placental-umbilical cord complex of a donor, the placental-umbilical cord complex having a plurality of components, the method comprising:

a) effecting a transaction whereby the donor donates a first set of components of the placental-chord complex;

b) providing to the donor a private banking service for a second set of components of the placental-chord complex,

wherein said first and second sets are distinct.

21. The method of claim 20 wherein said first set of donated components includes cord blood stem cells and the second set of privately banked components includes Wharton'"'"'s Jelly derived cells.

22. The method of claim 20 wherein said first set of donated components includes Wharton'"'"'s Jelly derived cells and the second set of privately banked components includes cord blood stem cells.

23. The method of claim 20 wherein said first set of donated components includes at least one generic biomaterial and said second set of privately banked components includes at least one sample of individual undifferentiated or partially differentiated cells.

24. The method of claim 23 wherein said generic biomaterial is selected from the group consisting of vascular tissue, extra-cellular matrix material, cord blood plasma, membranes, enzymes and amniotic fluid.

25. The method of claim 20 wherein a decision of which said components are to be donated and which said components are to be privately banked is carried out in accordance with at least one of donor type information, economic data of the donor, and pricing data of said components of said placenta-umbilical cord complex.

26. The method of claim 25 wherein said pricing data is received via an electronic price data feed.

27. The method of claim 25 wherein mesenchymal stem cells are privately banked if there is an elevated risk of a neurological disease.

28. The method of claim 24 wherein hematopoietic stem cells are privately banked if there is an elevated risk of a cancer.

29. The method of claim 20 further comprising:

c) computing a price of the transaction associated with said donating and said banking.

30. The method of claim 20 further comprising:

c) generating formalized contract text describing a transaction associated with said donating and said banking.

31. A method of determining a price of a financial transaction involving several distinct types of stem cells derived from the placenta-umbilical cord complex of a donor, the method comprising:

a) determining a cost of privately banking first set of samples of stem cells derived from the placenta-umbilical cord complex of the donor;

b) determining a market value of a second set of samples of stem cells derived from the placenta-umbilical cord complex of the donor, said first set and said second set of cells having different stem cell type profile;

c) determining the price of the stem cell transaction by computing a function of said cost of said private banking of said first set of stem cells and said market value of said second set of stem cells.

32. The method of claim 31 wherein said price of said stem cell transaction is further determined in accordance with costs testing at least one of the donor and a family member of the donor.

33. The method of claim 31 further comprising:

d) determining a market value of one or more generic biomaterials derived from the placenta-umbilical cord complex of the donor,

wherein said determining of said price of stem cell transaction is carried out in accordance with said market value of said one or more generic biomaterials.

34. The method of claim 31 wherein said market value of said second set of samples is determined in accordance with at least one of a medical history of the donor, a medical history of a family member of the donor and a genetic profile of the donor.

35. A method of determining a price of a financial transaction involving several distinct components of the placenta-umbilical cord complex of a donor, the method comprising:

a) determining a cost of privately banking first set of components of the placenta-umbilical cord complex of the donor;

b) determining a market value of a second set of components derived from the placenta-umbilical cord complex of the donor, said first set and said second set of components being distinct, said second said of components including a generic biomaterial; and

c) determining the price of the financial transaction by computing a function of said cost of said private banking of said first set of components and said market value of said second set of components.

36. A method of maintaining a computer-based registry different types of undifferentiated or partially differentiated cells derived from different locations in the placenta-umbilical cord complex, the method comprising:

a) creating a new donor record for a potential donor in a placenta-cord complex cells database of the registry;

b) storing donor identification information in the new record;

c) storing sample set identification information in the new record, said sample set including a plurality of samples of distinct stem cell types of the placenta-umbilical cord complex;

d) collecting the sample set from the donor;

e) obtaining donor type information and storing said donor type information in the new record; and

f) storing an availability indication with the new record to indicate which said stem cell types are available for public use;

g) storing the collected sample set in a bank such that individual samples of distinct stem cell types can be obtained from the bank using the stored sample set identification information; and

h) modifying the availability indication for a particular donor record when the availability for public use of at least one type of stem cells changes.

37. A method of utilizing the placenta-umbilical cord complex of a donor, the method comprising:

a) testing for disease at least one of the donor and a relative of the donor; and

b) if results of said testing indicates a disease free state,

i) privately banking stem cells of the placenta-umbilical cord complex; and

ii) offering for sale generic biomaterials of the placenta-umbilical cord complex.

38. A computerized system for determining allocation parameters for a placenta-umbilical chord complex of a donor, the system comprising:

a) a data storage unit adapted to store data about the donor and pricing data about a plurality of placenta chord complex components, said about the donor including economic data and medical-related data;

b) a processing unit for determining a first set of components to be donated and a second set of components to be privately banked,

wherein said determining is carried out in accordance with said pricing data.

39. The method of claim 38 wherein said determining is further carried out in accordance with at least one of said economic data and said medical data of said donor.

40. The system of claim 38 wherein said processing unit is further operative to value a transaction associated with said donating and private banking.

41. The system of claim 39 wherein said processing unit is operative to value said transaction in accordance with prices of testing at least one of the donor, the relative of the donor and a component of said placenta-umbilical chord complex.

42. The system of claim 38 wherein said economic data includes at least one of sum of money the donor is willing to pay, economic status of the donor, and an insurance status of the donor.

43. The system of claim 38 further comprising:

c) a contract generation module for generating formal contract text for the transaction associated with said donating and private banking.

44. The system of claim 43 further comprising;

d) an inventory tracking system for tracking quantities of a plurality of separately stored components of said placenta-umbilical cord complex.

45. The system of claim 43 further comprising:

e) an on-line sales portal for offering for sale said stored components.

46. The system of claim 45 wherein said on-line sales portal includes

i) a first user interface adapted to receive orders for samples of individual undifferentiated or partially differentiated cells extracted from said placenta-umbilical cord complex, and

ii) a second user interface adapted to receive orders for generic biomaterials derived form said placenta-umbilical cord complex.

43-1. A biological material data management system comprising:

a) a data input adapted to receive donor data including an identification of a donor;

b) a transaction logger for logging for each said donor transaction data wherein a plurality of components of placenta-chord complex of the placenta-umbilical cord complex is recovered and transferred; and

c) a data retrieval engine for retrieving a record relating each said component of a respective said placenta-chord complex to a respective said donor.

47. A computer-readable medium or combination of computer-readable media, containing a program for determining a price of a financial transaction involving several distinct types of stem cells derived from the placenta-umbilical cord complex of a donor, the program comprising code to effect:

a) determining a cost of privately banking first set of samples of stem cells derived from the placenta-umbilical cord complex of the donor;

b) determining a market value of a second set of samples of stem cells derived from the placenta-umbilical cord complex of the donor, said first set and said second set of cells having different stem cell type profile; and

c) determining the price of the stem cell transaction by computing a function of said cost of said private banking of said first set of stem cells and said market value of said second set of stem cells.

48. A computer-readable medium or combination of computer-readable media, containing a program for determining a price of a financial transaction involving several distinct components of the placenta-umbilical cord complex of a donor, the program comprising code to effect:

a) determining a cost of privately banking first set of components of the placenta-umbilical cord complex of the donor;

b) determining a market value of a second set of components derived from the placenta-umbilical cord complex of the donor, said first set and said second set of components being distinct, said second said of components including a generic biomaterial; and

c) determining the price of the financial transaction by computing a function of said cost of said private banking of said first set of components and said market value of said second set of components.

49. A computer-readable medium or combination of computer-readable media, containing a program for maintaining a computer-based registry different types of undifferentiated or partially differentiated cells derived from different locations in the placenta-umbilical cord complex, the program comprising code to effect:

a) creating a new donor record for a potential donor in a placenta-cord complex cells database of the registry;

b) storing donor identification information in the new record;

c) storing sample set identification information in the new record, said sample set including a plurality of samples of distinct stem cell types of the placenta-umbilical cord complex;

d) storing donor type information in the new record; and

e) storing an availability indication with the new record to indicate which said stem cell types are available for public use.

50. The computer-readable medium or combination of computer-readable media as in claim 49 wherein the program further comprises code to effect:

h) modifying the availability indication for a particular donor record when the availability for public use of at least one type of stem cells changes.

51. A device for determining a price of a financial transaction involving several distinct types of stem cells derived from the placenta-umbilical cord complex of a donor, the device comprising:

a) means for determining a cost of privately banking first set of samples of stem cells derived from the placenta-umbilical cord complex of the donor;

b) means for determining a market value of a second set of samples of stem cells derived from the placenta-umbilical cord complex of the donor, said first set and said second set of cells having different stem cell type profile; and

c) means for determining the price of the stem cell transaction by computing a function of said cost of said private banking of said first set of stem cells and said market value of said second set of stem cells.

52. A device for determining a price of a financial transaction involving several distinct components of the placenta-umbilical cord complex of a donor, the device comprising:

a) means for determining a cost of privately banking first set of components of the placenta-umbilical cord complex of the donor;

b) means for determining a market value of a second set of components derived from the placenta-umbilical cord complex of the donor, said first set and said second set of components being distinct, said second said of components including a generic biomaterial; and

c) means for determining the price of the financial transaction by computing a function of said cost of said private banking of said first set of components and said market value of said second set of components.

53. A device for maintaining a computer-based registry different types of undifferentiated or partially differentiated cells derived from different locations in the placenta-umbilical cord complex, the device comprising:

a) means for creating a new donor record for a potential donor in a placenta-cord complex cells database of the registry;

b) means for storing donor identification information in the new record;

c) means for storing sample set identification information in the new record, said sample set including a plurality of samples of distinct stem cell types of the placenta-umbilical cord complex;

d) means for storing donor type information in the new record; and

e) means for storing an availability indication with the new record to indicate which said stem cell types are available for public use.

54. The device of claim 53 further comprising:

h) means for modifying the availability indication for a particular donor record when the availability for public use of at least one type of stem cells changes.